Who Buys Cisplatin from India — 584 Importers Behind a $12.8M Market
India's cisplatin import market is served by 584 active buyers who collectively imported $12.8M across 1,701 shipments. UKRPHARMGROUP LLC (HUNGARY) leads with a 10.1% market share, followed by FRESENIUS KABI TAIWAN LTD. and CSP MYLAN IRELAND LTD. The top 5 buyers together control 24.3% of total import value, reflecting a moderately competitive buyer landscape.
Top Cisplatin Importers — Ranked by Import Value
UKRPHARMGROUP LLC (HUNGARY) is the leading cisplatin importer from India, holding a 10.1% share of the $12.8M market across 1,701 shipments from 584 buyers. The top 5 buyers — UKRPHARMGROUP LLC (HUNGARY), FRESENIUS KABI TAIWAN LTD. (TAIWAN), CSP MYLAN IRELAND LTD (FRANCE), FRESENIUS KABI TAIWAN LTD., (TAIWAN), XXCORXXHEAXXHCAXX INXX (CANADA) — collectively control 24.3% of total import value.
Top Cisplatin Buyers & Importers
Ranked by import value · 584 active buyers · Indian Customs (DGFT) data
| # | Buyer & Formulations | Value | Suppliers | Share |
|---|---|---|---|---|
| 1 | UKRPHARMGROUP LLCHUNGARY CISPLATIN VENUS PHARMA 100MG/100ML | $1.3M | 5 | 10.1% |
| 2 | FRESENIUS KABI TAIWAN LTD.TAIWAN CISPLATIN INJ 1 MG/ML 100 MLKEMOPLAT BP INJ. 50MG/50MLKEMOPLAT BP INJ. 50MG/50ML V | $680.8K | 5 | 5.3% |
| 3 | CSP MYLAN IRELAND LTDFRANCE CISPLATIN 1MG/ML 100ML P1 ACO-FRANCECISPLATIN 1MG/ML 100ML P1 (ACO-FRANCECISPLATIN VIATRIS 1MG 50ML 1S VIA FRANCE TAX VAL 4080811.48 | $457.6K | 5 | 3.6% |
| 4 | FRESENIUS KABI TAIWAN LTD.,TAIWAN CISPLATIN INJ 1 MG/ML 100 MLKEMOPLAT BP INJ. 50MG/50MLKEMOPLAT BP INJ. 50MG/50ML V | $347.3K | 5 | 2.7% |
| 5 | XXCORXXHEAXXHCAXX INXXCANADA CISPLATIN INJ 1 MG/ML 100 MLCISPLATIN INJECTION 100MG X 1 100MLCISPLATIN INJECTION 100MG/100ML | $336.3K | 5 | 2.6% |
| 6 | SCIEGEN PHARMACEUTICALS INCUNITED STATES CISPLATIN INJ 1 MG/ML 100 MLCISPLATIN INJECTION 100MG X 1 100MLCISPLATIN INJECTION 100MG/100ML | $329.4K | 5 | 2.6% |
| 7 | FRESENIUS KABI (THAILAND) LTDTHAILAND CISPLATIN INJ 1 MG/ML 100 MLKEMOPLAT BP INJ. 50MG/50MLKEMOPLAT BP INJ. 50MG/50ML V | $310.5K | 5 | 2.4% |
| 8 | FRESENIUS KABI TAIWAN LIMITEDTAIWAN CISPLATIN INJ 1 MG/ML 100 MLKEMOPLAT BP INJ. 50MG/50MLKEMOPLAT BP INJ. 50MG/50ML V | $287.6K | 5 | 2.2% |
| 9 | FRESENIUS KABI TAIWAN LTDTAIWAN CISPLATIN INJ 1 MG/ML 100 MLKEMOPLAT BP INJ. 50MG/50MLKEMOPLAT BP INJ. 50MG/50ML V | $275.8K | 5 | 2.1% |
| 10 | H B C LVIETNAM CISPLATIN INJ 1 MG/ML 100 MLCISPLATIN INJECTION 100MG X 1 100MLCISPLATIN INJECTION 100MG/100ML | $231.8K | 5 | 1.8% |
| 11 | PHARMACIE CENTRALE DES HOPITAUX (PCALGERIA | $214.1K | 5 | 1.7% |
| 12 | ROPSOHN THERAPEUTICS SASCOLOMBIA CISPLATIN INJECTION BP 50 MG/100 ML E.CISPLATIN INJECTION BP 50MG 50MLCISPLATIN INJECTION BP 50MG/50ML | $202.3K | 5 | 1.6% |
| 13 | FOSUN PHARMA USA INCUNITED STATES CISPLATIN INJ 1 MG/ML 100 MLCISPLATIN INJECTION 100MG X 1 100MLCISPLATIN INJECTION 100MG/100ML | $200.6K | 5 | 1.6% |
| 14 | XXCORXXHEAXXHCAXX PTXXLIMITEDAUSTRALIA CISPLATIN INJ 1 MG/ML 100 MLCISPLATIN INJECTION 100MG X 1 100MLCISPLATIN INJECTION 100MG/100ML | $159.6K | 5 | 1.2% |
| 15 | ACCORD HEALTHCARE INCCANADA CISPLATIN INJ 1 MG/ML 100 MLCISPLATIN INJECTION 100MG X 1 100MLCISPLATIN INJECTION 100MG/100ML | $148.5K | 5 | 1.2% |
Related Analysis
Market Analysis: Top Importing Countries & Importers
Comprehensive geographic market intelligence dashboard
Which companies are buying Cisplatin — and from which countries?
Flow of Cisplatin exports from India: each country's share and the named importers behind the numbers
Cisplatin — Buyer Countries to Key Importers
Trade flow: top importing countries → named buyer companies
Market Analysis: Top Importing Countries & Their Importers
1Taiwan
Taiwan emerges as the first largest importing country, achieving a total trade value of $1.6M through 20 shipments. This represents a market share of 12.4% of the total market activity, demonstrating their significant presence in the industry.
Top Importers: Taiwan has a diverse importer base, with their top importers including:
• FRESENIUS KABI TAIWAN LTD. - $680.8K (42.8% of country's total business)
• FRESENIUS KABI TAIWAN LTD., - $347.3K (21.8% of country's total business)
• FRESENIUS KABI TAIWAN LIMITED - $287.6K (18.1% of country's total business)
• FRESENIUS KABI TAIWAN LTD - $275.8K (17.3% of country's total business)
Key Insight: Taiwan demonstrates strong market positioning with an average shipment value of $79.6K, indicating premium pricing strategy compared to the market average of $7.6K.
Taiwan is a key market for Cisplatin imports, representing 12.4% of total trade value.
2Hungary
Hungary emerges as the second largest importing country, achieving a total trade value of $1.4M through 4 shipments. This represents a market share of 10.7% of the total market activity, demonstrating their significant presence in the industry.
Top Importers: Hungary has a diverse importer base, with their top importers including:
• UKRPHARMGROUP LLC - $1.3M (94.7% of country's total business)
Key Insight: Hungary demonstrates strong market positioning with an average shipment value of $343.7K, indicating premium pricing strategy compared to the market average of $7.6K.
Hungary is a key market for Cisplatin imports, representing 10.7% of total trade value.
3France
France emerges as the third largest importing country, achieving a total trade value of $922.2K through 10 shipments. This represents a market share of 7.2% of the total market activity, demonstrating their significant presence in the industry.
Top Importers: France has a diverse importer base, with their top importers including:
• CSP MYLAN IRELAND LTD - $457.6K (49.6% of country's total business)
Key Insight: France demonstrates strong market positioning with an average shipment value of $92.2K, indicating premium pricing strategy compared to the market average of $7.6K.
France is a key market for Cisplatin imports, representing 7.2% of total trade value.
4United States
United States emerges as the fourth largest importing country, achieving a total trade value of $891.1K through 11 shipments. This represents a market share of 6.9% of the total market activity, demonstrating their significant presence in the industry.
Top Importers: United States has a diverse importer base, with their top importers including:
• SCIEGEN PHARMACEUTICALS INC - $329.4K (37.0% of country's total business)
• FOSUN PHARMA USA INC - $200.6K (22.5% of country's total business)
Key Insight: United States demonstrates strong market positioning with an average shipment value of $81.0K, indicating premium pricing strategy compared to the market average of $7.6K.
United States is a key market for Cisplatin imports, representing 6.9% of total trade value.
5Thailand
Thailand emerges as the fifth largest importing country, achieving a total trade value of $876.5K through 6 shipments. This represents a market share of 6.8% of the total market activity, demonstrating their significant presence in the industry.
Top Importers: Thailand has a diverse importer base, with their top importers including:
• FRESENIUS KABI (THAILAND) LTD - $310.5K (35.4% of country's total business)
Key Insight: Thailand demonstrates strong market positioning with an average shipment value of $146.1K, indicating premium pricing strategy compared to the market average of $7.6K.
Thailand is a key market for Cisplatin imports, representing 6.8% of total trade value.
Buyer Segment Analysis
TransData Nexus Cisplatin buyer market intelligence
1Buyer Segment Analysis
The importers of Cisplatin from India can be categorized into several segments:
1. Pharmaceutical Distributors: Entities like UKRPHARMGROUP LLC (Hungary) and FRESENIUS KABI TAIWAN LTD. (Taiwan) fall into this category. These distributors procure large volumes of Cisplatin to supply to various healthcare providers, including hospitals and clinics. Their purchasing patterns are characterized by bulk orders to meet the consistent demand from their client base.
2. Contract Manufacturers: Companies such as CSP MYLAN IRELAND LTD (France) and SCIEGEN PHARMACEUTICALS INC (United States) are contract manufacturers. They import Cisplatin as an active pharmaceutical ingredient (API) for formulation into finished dosage forms. Their procurement is typically aligned with production schedules and client contracts, leading to periodic, large-scale purchases.
3. Hospital Groups: Entities like FRESENIUS KABI (THAILAND) LTD (Thailand) represent hospital groups that import Cisplatin directly for use within their network of healthcare facilities. Their buying behavior is driven by patient treatment needs, resulting in regular, moderate-sized orders to maintain adequate stock levels.
4. Re-exporters: Some companies, such as H B C L (Vietnam), may act as re-exporters, importing Cisplatin for distribution to neighboring countries. Their order patterns can be irregular, influenced by regional demand fluctuations and trade agreements.
Understanding these segments is crucial for tailoring marketing strategies and supply chain logistics to meet the specific needs and behaviors of each buyer type.
Country-Specific Import Regulations
TransData Nexus Cisplatin buyer market intelligence
1Country-Specific Import Regulations
Taiwan
1. Regulatory Authority: Taiwan Food and Drug Administration (TFDA).
2. Import Registration Process: Importers must submit a drug registration application to the TFDA, including documentation on product quality, safety, and efficacy.
3. Estimated Timeline: The registration process typically takes 12 to 18 months.
4. Import Tariff/Duty: Pharmaceutical products under HS code 30049047 are generally subject to a 0% import duty in Taiwan.
Hungary
1. Regulatory Authority: National Institute of Pharmacy and Nutrition (OGYÉI).
2. Import Registration Process: Applicants must submit a marketing authorization application to OGYÉI, providing comprehensive data on the drug's quality, safety, and efficacy.
3. Estimated Timeline: The process usually takes 210 days, as per European Medicines Agency (EMA) guidelines.
4. Import Tariff/Duty: As an EU member, Hungary applies a 0% import duty on pharmaceutical products under HS code 30049047.
France
1. Regulatory Authority: French National Agency for Medicines and Health Products Safety (ANSM).
2. Import Registration Process: Importers must obtain a marketing authorization from ANSM, involving submission of a dossier detailing the drug's quality, safety, and efficacy.
3. Estimated Timeline: The evaluation process typically takes 210 days, in line with EMA standards.
4. Import Tariff/Duty: France, as part of the EU, imposes a 0% import duty on pharmaceutical products under HS code 30049047.
United States
1. Regulatory Authority: U.S. Food and Drug Administration (FDA).
2. Import Registration Process: Importers must submit a New Drug Application (NDA) or Abbreviated New Drug Application (ANDA) to the FDA, providing comprehensive data on the drug's quality, safety, and efficacy.
3. Estimated Timeline: The FDA review process typically takes 10 months for standard applications.
4. Import Tariff/Duty: Pharmaceutical products under HS code 30049047 are generally subject to a 0% import duty in the United States.
Thailand
1. Regulatory Authority: Thai Food and Drug Administration (Thai FDA).
2. Import Registration Process: Importers must submit a drug registration application to the Thai FDA, including documentation on product quality, safety, and efficacy.
3. Estimated Timeline: The registration process typically takes 12 to 18 months.
4. Import Tariff/Duty: Pharmaceutical products under HS code 30049047 are generally subject to a 0% import duty in Thailand.
Demand Drivers & Market Opportunity
TransData Nexus Cisplatin buyer market intelligence
1Demand Drivers & Market Opportunity
The demand for Cisplatin in importing countries is primarily driven by the prevalence of cancers for which Cisplatin is a standard treatment, such as testicular, ovarian, bladder, and lung cancers. According to the World Health Organization (WHO), cancer remains a leading cause of morbidity and mortality worldwide, with approximately 19.3 million new cases and 10 million cancer-related deaths reported in 2020. This high disease burden necessitates the continuous procurement of effective chemotherapeutic agents like Cisplatin.
Government healthcare programs and the expansion of universal health coverage also significantly influence Cisplatin demand. Many countries have incorporated Cisplatin into their national essential medicines lists, aligning with the WHO Essential Medicines List, which includes Cisplatin as a core medicine for cancer treatment. This inclusion often leads to tender-based purchasing mechanisms, where governments or large healthcare providers issue tenders to procure substantial quantities of Cisplatin, ensuring its availability in public healthcare facilities. The presence of 584 buyers across 130 countries, as per our data, underscores the global reliance on Cisplatin and highlights the market opportunities for suppliers.
Common Questions — Cisplatin Buyers & Importers
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
QWho is the largest cisplatin buyer importing from India?
Based on import volume and value, UKRPHARMGROUP LLC (HUNGARY) leads with $1.3M in imports and a 10.1% market share — the highest of any single cisplatin importer. FRESENIUS KABI TAIWAN LTD. (TAIWAN) and CSP MYLAN IRELAND LTD (FRANCE) are the next largest buyers.
QHow many companies buy cisplatin from India?
There are 584 active cisplatin buyers importing from India, with a combined market of $12.8M across 1,701 shipments to 130 countries. The top 5 buyers hold 24.3% of total import value, while the remaining 579 buyers handle the other 75.7%.
QWhich countries import the most cisplatin from India?
The top importing countries for cisplatin from India are Taiwan (12.4%), Hungary (10.7%), France (7.2%), United States (6.9%), Thailand (6.8%). These markets represent the largest demand centres for Indian pharmaceutical exports of cisplatin, with buyers ranging from government procurement agencies to private pharmaceutical distributors.
QWhat is the average import order value for cisplatin from India?
The average import transaction value for cisplatin from India is $7.6K, with an average unit price of $4.29 per unit. Order sizes vary significantly based on buyer type — government tenders tend to be larger while private distributors place more frequent smaller orders.
Buyer Segment Analysis
TransData Nexus Cisplatin buyer market intelligence
1Buyer Segment Analysis
The importers of Cisplatin from India can be categorized into several segments:
1. Pharmaceutical Distributors: Entities like UKRPHARMGROUP LLC (Hungary) and FRESENIUS KABI TAIWAN LTD. (Taiwan) fall into this category. These distributors procure large volumes of Cisplatin to supply to various healthcare providers, including hospitals and clinics. Their purchasing patterns are characterized by bulk orders to meet the consistent demand from their client base.
2. Contract Manufacturers: Companies such as CSP MYLAN IRELAND LTD (France) and SCIEGEN PHARMACEUTICALS INC (United States) are contract manufacturers. They import Cisplatin as an active pharmaceutical ingredient (API) for formulation into finished dosage forms. Their procurement is typically aligned with production schedules and client contracts, leading to periodic, large-scale purchases.
3. Hospital Groups: Entities like FRESENIUS KABI (THAILAND) LTD (Thailand) represent hospital groups that import Cisplatin directly for use within their network of healthcare facilities. Their buying behavior is driven by patient treatment needs, resulting in regular, moderate-sized orders to maintain adequate stock levels.
4. Re-exporters: Some companies, such as H B C L (Vietnam), may act as re-exporters, importing Cisplatin for distribution to neighboring countries. Their order patterns can be irregular, influenced by regional demand fluctuations and trade agreements.
Understanding these segments is crucial for tailoring marketing strategies and supply chain logistics to meet the specific needs and behaviors of each buyer type.
Country-Specific Import Regulations
TransData Nexus Cisplatin buyer market intelligence
1Country-Specific Import Regulations
Taiwan
1. Regulatory Authority: Taiwan Food and Drug Administration (TFDA).
2. Import Registration Process: Importers must submit a drug registration application to the TFDA, including documentation on product quality, safety, and efficacy.
3. Estimated Timeline: The registration process typically takes 12 to 18 months.
4. Import Tariff/Duty: Pharmaceutical products under HS code 30049047 are generally subject to a 0% import duty in Taiwan.
Hungary
1. Regulatory Authority: National Institute of Pharmacy and Nutrition (OGYÉI).
2. Import Registration Process: Applicants must submit a marketing authorization application to OGYÉI, providing comprehensive data on the drug's quality, safety, and efficacy.
3. Estimated Timeline: The process usually takes 210 days, as per European Medicines Agency (EMA) guidelines.
4. Import Tariff/Duty: As an EU member, Hungary applies a 0% import duty on pharmaceutical products under HS code 30049047.
France
1. Regulatory Authority: French National Agency for Medicines and Health Products Safety (ANSM).
2. Import Registration Process: Importers must obtain a marketing authorization from ANSM, involving submission of a dossier detailing the drug's quality, safety, and efficacy.
3. Estimated Timeline: The evaluation process typically takes 210 days, in line with EMA standards.
4. Import Tariff/Duty: France, as part of the EU, imposes a 0% import duty on pharmaceutical products under HS code 30049047.
United States
1. Regulatory Authority: U.S. Food and Drug Administration (FDA).
2. Import Registration Process: Importers must submit a New Drug Application (NDA) or Abbreviated New Drug Application (ANDA) to the FDA, providing comprehensive data on the drug's quality, safety, and efficacy.
3. Estimated Timeline: The FDA review process typically takes 10 months for standard applications.
4. Import Tariff/Duty: Pharmaceutical products under HS code 30049047 are generally subject to a 0% import duty in the United States.
Thailand
1. Regulatory Authority: Thai Food and Drug Administration (Thai FDA).
2. Import Registration Process: Importers must submit a drug registration application to the Thai FDA, including documentation on product quality, safety, and efficacy.
3. Estimated Timeline: The registration process typically takes 12 to 18 months.
4. Import Tariff/Duty: Pharmaceutical products under HS code 30049047 are generally subject to a 0% import duty in Thailand.
Demand Drivers & Market Opportunity
TransData Nexus Cisplatin buyer market intelligence
1Demand Drivers & Market Opportunity
The demand for Cisplatin in importing countries is primarily driven by the prevalence of cancers for which Cisplatin is a standard treatment, such as testicular, ovarian, bladder, and lung cancers. According to the World Health Organization (WHO), cancer remains a leading cause of morbidity and mortality worldwide, with approximately 19.3 million new cases and 10 million cancer-related deaths reported in 2020. This high disease burden necessitates the continuous procurement of effective chemotherapeutic agents like Cisplatin.
Government healthcare programs and the expansion of universal health coverage also significantly influence Cisplatin demand. Many countries have incorporated Cisplatin into their national essential medicines lists, aligning with the WHO Essential Medicines List, which includes Cisplatin as a core medicine for cancer treatment. This inclusion often leads to tender-based purchasing mechanisms, where governments or large healthcare providers issue tenders to procure substantial quantities of Cisplatin, ensuring its availability in public healthcare facilities. The presence of 584 buyers across 130 countries, as per our data, underscores the global reliance on Cisplatin and highlights the market opportunities for suppliers.
Official References & Regulatory Resources
- European Medicines Agency
- WHO Essential Medicines
- Invest India — Pharma Sector
- India Trade Statistics (DGFT)
Verify import regulations and drug registration requirements with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Buyer Identification: 584 global importers of Cisplatin identified from consignee fields in DGFT shipping bill records.
- 2.Import Value Analysis: Total import value aggregated from 1,701 individual shipping bill records. Values are FOB in USD.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
- 4.Geographic Distribution: Buyer imports distributed across 130 destination countries with market share per buyer calculated from capped values.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
1,701 Verified Shipments
584 buyers tracked
Expert-Reviewed
By pharmaceutical trade specialists